Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
Mena FN5h
KIND Presents Positive Results Of AND017 To Treat Anemia Associated With Chronic Kidney Disease In Two Phase II And Two Phase I
please read the posters from Kind's website . Last week FDA granted Orphan Drug Designation to this investigation drug in Sickle Cell Disease (SCD) treatment. About Anemia in Chronic Kidney Disease ...
Unicycive presents on development progress of oxylanthanum carbonate
Unicycive Therapeutics (UNCY) announced that multiple presentations were delivered at the American Society of Nephrology Kidney Week 2024 that ...
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
INDICATION XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response ...
Fox 5 San Diego13d
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Vafseo is approved for use in 37 countries. VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.